Exchange: NYSE·Updated 10:28 AM EDT

NVS News

News
all
press releases
Novartis Halts Experimental ALS Drug Trial but Acquires Brain Delivery Platform
Novartis halted its mid-stage ALS drug trial for VHB937 but exercised a $125 million option to acquire Sironax's brain delivery platform.read more...
Benzinga
More News
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.
Zacks
LEGN’s New CEO From Novartis Paves Way For Buyout Speculation
Legend’s new CEO Ingrid Zhang most recently served as chief commercial officer for Novartis International.
Stocktwits
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
Zacks
INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?
Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.
Zacks
AZN's Etcamah Fails Late-Stage Study for First-line Breast Cancer
AstraZeneca's Etcamah fails to improve PFS significantly in a phase III first-line breast cancer study, while its approved use remains unaffected.
Zacks
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
Key PointsNovartis recently announced bad news for its Lp(a)-lowering drug, pelacarsen...
Nasdaq News: Markets
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s
LLY's immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.
Zacks
4 Small-Cap Stocks with Catalysts Investors Can’t Ignore
The biopharma trade has entered a fascinating stretch. Investors continue to focus heavily on the industry's giants, including Novartis (NYSE:NVS), Eli Lilly (NYSE:LLY), and Amgen (NASDAQ:AMGN), but the latest market action is a reminder that some of the biggest percentage moves in biotechnology can come from much smaller companies. That is where the bull case for looking beyond the mega-caps begins. 24/7 Market News has urged investors to broaden the lens to smaller companies including Tenon Medical (NASDAQ:TNON), NeOnc Technologies Holdings (NASDAQ:NTHI), Opus Genetics (NASDAQ:IRD), and bioAffinity Technologies (NASDAQ:BIAF). These companies share one potentially important characteristic: their valuations can be heavily influenced by discrete clinical, regulatory, commercial, or financing milestones.
24-7 Market News
NVS Stock On Track For Worst Week In Over 7 Years After Two Trial Failures In A Week — Investor Reportedly Seeks Board Overhaul
David Samra, managing director at Artisan Partners, told Reuters that Chairman Giovanni Caforio should tighten oversight of acquisitions, add an acquisitions committee, and recruit stronger board talent.
Stocktwits

Advertisement|Remove ads.